Eli Lil­ly teams with Pieris on HER2+ tu­mors; Op­di­vo + Yer­voy best chemo in mesothe­lioma

De­spite the FDA putting a par­tial clin­i­cal hold on its lead pro­gram on­ly a few weeks ago, Boston-based Pieris Phar­ma­ceu­ti­cals is plow­ing for­ward with a new col­lab­o­ra­tion.

Pieris will work with Eli Lil­ly to fur­ther ad­vance stud­ies on PRS-343, a 4-1BB/HER2 bis­pe­cif­ic for HER2-pos­i­tive tu­mors, in com­bi­na­tion with the lat­ter’s ra­mu­cirum­ab and pa­cli­tax­el for the sec­ond-line treat­ment of pa­tients with HER2-pos­i­tive gas­tric can­cer in a sin­gle-arm, Phase II study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.